CELU
Price
$3.15
Change
+$0.12 (+3.96%)
Updated
Jul 21 closing price
Capitalization
75.44M
CYBN
Price
$8.03
Change
-$0.29 (-3.49%)
Updated
Jul 21 closing price
Capitalization
190.34M
Interact to see
Advertisement

CELU vs CYBN

Header iconCELU vs CYBN Comparison
Open Charts CELU vs CYBNBanner chart's image
Celularity
Price$3.15
Change+$0.12 (+3.96%)
Volume$328.35K
Capitalization75.44M
Cybin
Price$8.03
Change-$0.29 (-3.49%)
Volume$1M
Capitalization190.34M
CELU vs CYBN Comparison Chart in %
Loading...
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELU vs. CYBN commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELU is a Hold and CYBN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (CELU: $3.15 vs. CYBN: $8.03)
Brand notoriety: CELU and CYBN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELU: 118% vs. CYBN: 238%
Market capitalization -- CELU: $75.44M vs. CYBN: $190.34M
CELU [@Biotechnology] is valued at $75.44M. CYBN’s [@Biotechnology] market capitalization is $190.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELU’s FA Score shows that 0 FA rating(s) are green whileCYBN’s FA Score has 1 green FA rating(s).

  • CELU’s FA Score: 0 green, 5 red.
  • CYBN’s FA Score: 1 green, 4 red.
According to our system of comparison, both CELU and CYBN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELU’s TA Score shows that 6 TA indicator(s) are bullish while CYBN’s TA Score has 6 bullish TA indicator(s).

  • CELU’s TA Score: 6 bullish, 4 bearish.
  • CYBN’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, CYBN is a better buy in the short-term than CELU.

Price Growth

CELU (@Biotechnology) experienced а +40.63% price change this week, while CYBN (@Biotechnology) price change was +7.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.39%. For the same industry, the average monthly price growth was +15.71%, and the average quarterly price growth was +33.77%.

Industries' Descriptions

@Biotechnology (+2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYBN($190M) has a higher market cap than CELU($75.4M). CELU YTD gains are higher at: 51.442 vs. CYBN (-8.957). CELU has higher annual earnings (EBITDA): -21.59M vs. CYBN (-134.52M). CYBN has more cash in the bank: 136M vs. CELU (133K). CYBN has less debt than CELU: CYBN (0) vs CELU (69.1M). CELU has higher revenues than CYBN: CELU (48.2M) vs CYBN (0).
CELUCYBNCELU / CYBN
Capitalization75.4M190M40%
EBITDA-21.59M-134.52M16%
Gain YTD51.442-8.957-574%
P/E RatioN/AN/A-
Revenue48.2M0-
Total Cash133K136M0%
Total Debt69.1M0-
FUNDAMENTALS RATINGS
CELU vs CYBN: Fundamental Ratings
CELU
CYBN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
19
Undervalued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
3657
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a30

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYBN's Valuation (19) in the null industry is somewhat better than the same rating for CELU (61). This means that CYBN’s stock grew somewhat faster than CELU’s over the last 12 months.

CYBN's Profit vs Risk Rating (94) in the null industry is in the same range as CELU (100). This means that CYBN’s stock grew similarly to CELU’s over the last 12 months.

CYBN's SMR Rating (97) in the null industry is in the same range as CELU (99). This means that CYBN’s stock grew similarly to CELU’s over the last 12 months.

CELU's Price Growth Rating (36) in the null industry is in the same range as CYBN (57). This means that CELU’s stock grew similarly to CYBN’s over the last 12 months.

CELU's P/E Growth Rating (100) in the null industry is in the same range as CYBN (100). This means that CELU’s stock grew similarly to CYBN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELUCYBN
RSI
ODDS (%)
Bearish Trend 4 days ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
80%
Bullish Trend 4 days ago
83%
Momentum
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
74%
MACD
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
74%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 15 days ago
81%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
74%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
67%
Bullish Trend 4 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TCMFF1.730.48
+38.40%
Telecom Argentina S.A.
EPOAY21.350.58
+2.79%
Epiroc Aktiebolag
RIOCF13.100.16
+1.25%
Riocan Real Estate Investment Trust
ACNFF26.32N/A
N/A
Amsterdam Commodities N.V.
ELTP0.53-0.03
-5.09%
Elite Pharmaceuticals, Inc.

CELU and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELU has been loosely correlated with ACOG. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CELU jumps, then ACOG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELU
1D Price
Change %
CELU100%
+3.96%
ACOG - CELU
48%
Loosely correlated
-0.10%
SPRO - CELU
26%
Poorly correlated
-2.11%
NVCT - CELU
25%
Poorly correlated
+0.38%
GBIO - CELU
25%
Poorly correlated
+3.62%
CYBN - CELU
24%
Poorly correlated
-3.49%
More

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
-3.49%
ATAI - CYBN
43%
Loosely correlated
+9.29%
RXRX - CYBN
37%
Loosely correlated
+9.59%
ABSI - CYBN
36%
Loosely correlated
+12.50%
EYPT - CYBN
31%
Poorly correlated
+2.33%
ABCL - CYBN
30%
Poorly correlated
+15.21%
More